These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 35795339)
21. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Ling RR; Sim JJL; Tan FL; Tai BC; Syn N; Mucheli SS; Fan BE; Mitra S; Ramanathan K Transfus Med Rev; 2022 Jan; 36(1):16-26. PubMed ID: 34782209 [TBL] [Abstract][Full Text] [Related]
23. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M; Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505 [TBL] [Abstract][Full Text] [Related]
24. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients. Tang J; Grubbs G; Lee Y; Golding H; Khurana S Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337 [TBL] [Abstract][Full Text] [Related]
25. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients. Beraud M; Goodhue Meyer E; Lozano M; Bah A; Vassallo R; Brown BL Transfus Apher Sci; 2022 Jun; 61(3):103355. PubMed ID: 35063360 [TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105 [TBL] [Abstract][Full Text] [Related]
27. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428 [TBL] [Abstract][Full Text] [Related]
28. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208 [TBL] [Abstract][Full Text] [Related]
29. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384 [TBL] [Abstract][Full Text] [Related]
30. Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS-CoV-2 in a US-like population. Kostandova N; Drabo EF; Yenokyan K; Wesolowski A; Truelove S; Bloch EM; Tobian AAR; Vassallo RR; Bravo MD; Casadevall A; Lessler J; Lau B Transfusion; 2023 Jan; 63(1):92-103. PubMed ID: 36345608 [TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Convalescent Plasma Therapy in Severe or Critically Ill COVID-19 Patients: A Retrospective Cohort Study. Cho Y; Sohn Y; Hyun J; Baek Y; Kim M; Kim J; Ahn J; Jeong S; Ku N; Yeom JS; Ahn M; Oh D; Choi J; Kim S; Lee K; Song Y; Choi J Yonsei Med J; 2021 Sep; 62(9):799-805. PubMed ID: 34427065 [TBL] [Abstract][Full Text] [Related]
32. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
33. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Baldeón ME; Maldonado A; Ochoa-Andrade M; Largo C; Pesantez M; Herdoiza M; Granja G; Bonifaz M; Espejo H; Mora F; Abril-López P; Armijo LKR; Pacheco V; Salazar R; Reinthaller S; Zertuche F; Fornasini M Transfus Med; 2022 Apr; 32(2):153-161. PubMed ID: 35001439 [TBL] [Abstract][Full Text] [Related]
34. Convalescent plasma transfusion in severe COVID-19 patients: Clinical and laboratory outcomes. Abdullah MR; Alam Faizli A; Adzaludin NS; Abu Amin N; Misnan NA; Low LL Malays J Pathol; 2023 Apr; 45(1):87-95. PubMed ID: 37119249 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection. Escobedo-Sánchez PE; de la Cruz-Hernández I; Ramos-García M; Sánchez-Yedra I; García-Vázquez C; Guzmán-Priego CG; García-Vidrios MV; Olvera-Hernández V; Mendoza-García Y; Ble-Castillo JL Med Clin (Barc); 2023 Oct; 161(8):323-329. PubMed ID: 37423879 [TBL] [Abstract][Full Text] [Related]
36. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. Erkurt MA; Sarici A; Berber İ; Kuku İ; Kaya E; Özgül M Transfus Apher Sci; 2020 Oct; 59(5):102867. PubMed ID: 32620409 [TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study. Albalawi M; Zaidi SZA; AlShehry N; AlAskar A; Zaidi ARZ; Abdallah RNM; Salam A; AlSagheir A; AlMozain N; Elgohary G; Batarfi K; Alfaraedi A; Khojah O; Al-Ansari R; Alfaraj M; Dayel A; Al Bahrani A; Abdelhameed AN; Alhumaidan H; Al-Otaibi JM; Radwi G; Raizah A; Shatry H; Alsaleh S; AlZahrani H; Al-Hashmi H JMIR Res Protoc; 2020 Oct; 9(10):e23543. PubMed ID: 32903199 [TBL] [Abstract][Full Text] [Related]